BNC210

BNC210

Systematic (IUPAC) name
L-Isoleucyl-L-tryptophan
Clinical data
Legal status	Investigational
Identifiers
ATC code	None
PubChem	CID 7019084
ChemSpider	5382052
Chemical data
Formula	C17H23N3O3
Molecular mass	317.383 g/mol
SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
InChI InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1 Key:BVRPESWOSNFUCJ-LKTVYLICSA-N

BNC210 (also known as IW-4123 during it's time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug which functions via negative allosteric modulation of the alpha 7 nicotinic acetylcholine receptor,^[1] by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.^[2] It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.^[3]

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals, where it was known as IW-2143. IW-2143 was undergoing phase I clinical trials in the United States,^[4] but in November 2014, was released back to Bionics in a mutual agreement.^[5] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

It is currently undergoing clinical trials in Rennes, France, at Biotrial International.^[6] A phase II trial is planned to begin by April 2015.^[7]

References